Novo Nordisk A/S vs Johnson & Johnson
Side-by-side stock comparison based on AI earnings call analysis
Which stock has stronger management signals?
Johnson & Johnson currently has the stronger revenue growth signal.
Novo Nordisk A/S and Johnson & Johnson show active capex signals based on earnings call analysis.
No strong fundraising signal is currently visible for either company.
| Metric | Novo Nordisk A/S | Johnson & Johnson |
|---|---|---|
| Current Price | ₹45.51 | ₹230.8 |
| Market Cap | ₹2.03 L Cr. | ₹5.56 L Cr. |
| Industry | Pharmaceuticals | Pharmaceuticals |
| P/E Ratio | 10.373239 | 26.672073 |
| ROE (%) | — | — |
| Debt/Equity | — | — |
| Sales Growth 5Y (%) | — | — |
| Profit Growth 5Y (%) | — | — |
| Promoter Holding (%) | — | — |
| Revenue Rank | Rank 4 | Rank 3 |
| Margin Rank | Rank 4 | Rank 4 |
| Signal | — | — |
| Capex | Yes | Yes |
| Fundraise | No information | No information |